

reduce the risk of hospitalization for heart failure. The device is proposed to be used in patients who have already been treated with all other device and drug treatment options appropriate for them.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. All electronic and written submissions submitted to the Docket (see **ADDRESSES**) on or before November 14, 2025, will be provided to the Committee. Oral presentations from the public will be scheduled on December 3, 2025, between approximately 2 p.m. and 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 3, 2025. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 10, 2025.

For press inquiries, please contact the FDA Newsroom at www.fda.gov/news-events/fda-newsroom.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a

disability, please contact CDR Daniel Bailey at Daniel.Bailey@fda.hhs.gov or 301-796-0048 at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*). This meeting notice also serves as notice that, pursuant to 21 CFR 10.19, the requirements in 21 CFR 14.22(b), (f), and (g) relating to the location of advisory committee meetings are hereby waived to allow for this meeting to take place using an online meeting platform. This waiver is in the interest of allowing greater transparency and opportunities for public participation, in addition to convenience for advisory committee members, speakers, and guest speakers. The conditions for issuance of a waiver under 21 CFR 10.19 are met.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025-19762 Filed 11-3-25; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF THE INTERIOR

Bureau of Ocean Energy Management

[Docket No. BOEM-2025-0020]

Notice on Outer Continental Shelf Oil and Gas Lease Sales

AGENCY: Bureau of Ocean Energy Management, Interior.

ACTION: List of restricted joint bidders.

SUMMARY: Pursuant to the Energy Policy and Conservation Act of 1975 and the Bureau of Ocean Energy Management's (BOEM) regulatory restrictions on joint bidding, BOEM is publishing this list of restricted joint bidders. Each entity within one of the following groups is restricted from bidding with any entity in any of the other groups listed below at Outer Continental Shelf oil and gas lease sales held during the bidding period of November 1, 2025, through April 30, 2026.

DATES: This list of restricted joint bidders covers the bidding period of November 1, 2025, through April 30, 2026, and succeeds all prior published lists.

SUPPLEMENTARY INFORMATION:

Group I

BP America Production Company
BP Exploration & Production Inc.
BP Products North America, Inc.

Group II

Chevron Corporation
Chevron U.S.A. Inc.
Unocal Corporation
Union Oil Company of California
Noble Energy, Inc.
Hess Corporation
Chevron Midcontinent, L.P.

Group III

Eni Marketing Inc.
Eni BB Petroleum Inc.
Eni US Operating Co. Inc.
Eni Petroleum Co. Inc.
Eni Next LLC
Eni USA Gas Marketing LLC
Eni GoM LLC
Versalis Americas Inc.
Eni Trading & Shipping Inc.

Group IV

Equinor ASA
Equinor Gulf of Mexico LLC
Equinor USA E&P Inc.

Group V

Exxon Mobil Corporation
ExxonMobil Upstream Company

Group VI

Shell USA, Inc.
Shell Offshore Inc.
SWEPI LP
Shell Frontier Oil & Gas Inc.
SOI Finance Inc.
Shell Gulf of Mexico Inc.

Group VII

TotalEnergies E&P USA, Inc.
TotalEnergies SE

Even if an entity does not appear on the above list, BOEM may disqualify and reject certain joint or single bids submitted by an entity if that entity is chargeable for the prior production period with an average daily production in excess of 1.6 million barrels of crude oil, natural gas, and natural gas liquids. See 30 CFR 556.512.

Authority: 42 U.S.C. 6213; and 30 CFR 556.511-556.515.

Matthew N. Giacona,

Acting Director, Bureau of Ocean Energy Management.

[FR Doc. 2025-19780 Filed 11-3-25; 8:45 am]

BILLING CODE 4340-98-P

NATIONAL CREDIT UNION ADMINISTRATION

Sunshine Act Meetings

TIME AND DATE: 1:00 p.m., Wednesday, November 5, 2025.